相关实验视频

Updated: Jun 7, 2025

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

化疗药物输送纳米平台开发:从物理化学到临床前评估

Orestis Kontogiannis^1,2, Dimitrios Selianitis², Konstantinos Palikaras³

¹Department of Basic Medical Science, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

International journal of molecular sciences

|November 9, 2024

概括

这项研究开发了一种用于化疗药物的新型聚合物/表面活性剂纳米载体,显示出高药载荷和持续释放. 这种安全且生物相容的纳米载体适合静脉注射.

科学领域:

材料科学材料科学材料科学
纳米技术纳米技术
制药科学制药科学

背景情况:

开发有效的纳米载体用于溶解不良的化疗药物至关重要.
表面活性剂-共聚合物系统为先进的药物输送平台提供了潜力.
了解生物环境中的纳米载体行为对于临床转化至关重要.

研究的目的:

调查表面活性剂和Pluronic 188的协同行为,用于新型纳米载体配方.
评估混合纳米载体的物理化学特性,稳定性和药物输送能力.
评估开发的纳米载体的体外和体外安全性和生物相容性.

主要方法:

使用四种表面活性剂和Pluronic 188在不同比例下制备混合纳米载体.
物理化学性质的表征,包括水力动力半径和多分散度指数.
评估药物载荷能力,持续释放特征以及富含蛋白质介质中的稳定性.
在体外细胞毒性和基因毒性测定使用HEK293,HCT-116和MCF-7细胞系.
在*Caenorhabditis elegans*中进行了体内毒性评估.

主要成果:

一个单一的优化纳米配方显示了高药物负载 (≥75%EE) 和持续释放的甲状腺素.
纳米载体的平均水力动力半径<70 nm,PDI为0.219,并且没有蛋白质复合.
在体外和体内研究证实了空纳米载体的安全性和生物相容性.
开发的系统显示适用于静脉和肌肉内注射.

结论:

表面活性剂和Pluronic 188的协同组合产生了有效的纳米载体,用于化疗输送.
优化的纳米载体具有有利的物理化学特性和出色的生物相容性.
这种整体方法为先进的药物输送系统提供了一个有前途的平台.

关键词:

三维细胞培养的3D细胞培养这里是C. elegans.进行MTS测定.多元体 188 188 是一个多元体.在实时PCR中进行实时PCR.薄膜水化液的使用方法

更多相关视频

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

相关概念视频

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Biopharmaceutics and Pharmacokinetics: Overview

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...